Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals announced that its Board of Directors has approved a stock repurchase plan on Thursday, August 10th 2017, which allows the company to buyback $20,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board believes its stock is undervalued.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its quarterly earnings results on Wednesday, August, 9th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.05. The company had revenue of $65.20 million for the quarter, compared to analysts' expectations of $63.40 million. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The firm's revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.23 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

6 analysts have issued 12 month target prices for Amphastar Pharmaceuticals' shares. Their predictions range from $16.00 to $29.00. On average, they expect Amphastar Pharmaceuticals' stock price to reach $19.83 in the next year. View Analyst Ratings for Amphastar Pharmaceuticals.

Here are some recent quotes from research analysts about Amphastar Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. " (5/16/2017)
• 2. Piper Jaffray Companies analysts commented, "Amphastar reported 4Q16 diluted EPS of $0.01 on revenues of $63.5M, compared to Street estimates of ($0.01) and $55.9M, respectively. Though the base business is facing some challenges as we move further into 2017 (i.e., uncertainty over the trajectory of generic enoxaparin; the potential removal of AMPH's injectable epinephrine given that it is an unapproved product), we nonetheless remain bullish on AMPH shares, given that the pipeline continues to advance and given our view that it very much has the potential to drive transformative longer-term cash generation (AMPH also being one of the few generics companies solely focused on more complex dosage forms also doesn't hurt). We reiterate our Overweight rating and are lowering our PT to $20 from $22 (see below for more details)." (3/14/2017)
• 3. BMO Capital Markets analysts commented, " AMPH reported 4Q16 revenue of $63.5mm vs. BMO/consensus $56.5mm/ $55.9mm and adj. EPS of $0.01 vs. BMO/consensus $0.02/($0.01). Revenue upside was offset by lower gross margin and higher R&D. Without 2017 revenue/EPS guidance, there is some uncertainty with the numbers given a number of moving parts, including Enoxaparin sales, potential withdrawal of Epinephrine vials, overall pricing pressure, contribution from new approvals, and higher spending levels to invest in the pipeline. We are lowering estimates and our target goes to $16 from $18. The pipeline has value, but we await near-term execution." (3/14/2017)
• 4. Needham & Company LLC analysts commented, "While AMPH reported 4Q16 results that bested the Street's expectations on both top and bottom lines, the company has taken its lumps from the FDA over the last three months. Two recent CRLs (Primatene Mist and intranasal naloxone) have delayed two branded product opportunities by at least 12 months. FDA recently requested that AMPH discontinue the distribution of its epinephrine vial product, which generated $18.6MM in 2016 revenues. The last shot on goal in terms of potential near-term approvals is an ANDA product (undisclosed injectable), which AMPH mgmt expects will make meaningful sales contributions in 2017. The ANDA product pipeline is expected to make additional contributions in 2018. We maintain our Buy rating and adjust our PT to $18 (from $20) to account for a reduction in base business revenues." (3/14/2017)

Some companies that are related to Amphastar Pharmaceuticals include Innoviva (INVA), Impax Laboratories (IPXL), AKCEA THERAPEUT (AKCA), AMAG Pharmaceuticals (AMAG), Lannett Co (LCI), SciClone Pharmaceuticals (SCLN), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP), Teligent (TLGT), Collegium Pharmaceutical (COLL), Tetraphase Pharmaceuticals (TTPH), Corium International (CORI), Neos Therapeutics (NEOS), BioDelivery Sciences International (BDSI), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), Aralez Pharmaceuticals (ARLZ) and Marinus Pharmaceuticals (MRNS).

Amphastar Pharmaceuticals' management team includes the folowing people:

• Mary Ziping Luo Ph.D., Chief Operating Officer, Chief Scientist and Chairman of the Board
• Jason B. Shandell J.D., M.B.A., President, Director
• Jack Yongfeng Zhang Ph.D., Chief Executive Officer, Chief Science Officer, Director
• William J. Peters, Chief Financial Officer, Senior Vice President, Treasurer
• Diane G. Gerst, President, Amphastar Nanjing Pharmaceuticals Co., Ltd
• Marilyn J. Purchase, Corporate Executive Vice President of Operations and President, International Medication Systems, Ltd.
• Richard Koo CPA,, Independent Director
• Howard S. Lee Ph.D., Independent Director
• Floyd F. Petersen, Independent Director
• Richard Prins, Independent Director

Amphastar Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.80%), Vanguard Group Inc. (5.28%), Dimensional Fund Advisors LP (2.91%), Federated Investors Inc. PA (2.29%), State Street Corp (2.10%) and Teachers Advisors LLC (1.20%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Rothschild Asset Management Inc., Citadel Advisors LLC, Acadian Asset Management LLC, Cornerstone Capital Management Holdings LLC., BlackRock Inc., JPMorgan Chase & Co., State Street Corp and Russell Investments Group Ltd.. Company insiders that have sold Amphastar Pharmaceuticals stock in the last year include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins and Rong Zhou. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Vanguard Group Inc., UBS Asset Management Americas Inc., Citigroup Inc., Bank of Montreal Can, Argent Capital Management LLC, Fisher Asset Management LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Shares of Amphastar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Amphastar Pharmaceuticals stock can currently be purchased for approximately $15.22.